Vitamin D analogs as anti-carcinogenic agents

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Deltanoids (natural and synthetic vitamin D analogs) possess anti-proliferative, pro-differentiation, and pro-apoptotic properties, making them attractive for cancer chemoprevention and chemotherapy.
• The native vitamin D form, 1,25(OH)2D3, causes hypercalcemia at therapeutic doses, limiting its clinical use.
• Developing novel deltanoids aims to dissociate therapeutic benefits from toxic side effects.

Purpose of the Study:

• To explore the potential of deltanoids in cancer chemoprevention and chemotherapy.
• To review structural modifications and structure-activity relationships (SARs) of deltanoids.
• To discuss strategies for overcoming toxicity and enhancing therapeutic efficacy.

Main Methods:

• Review of existing literature on deltanoid design, VDR binding, and pharmacokinetic properties.
• Analysis of structure-activity relationships (SARs) based on modifications to the C,D-ring, A-ring, and C,D-ring side chain.
• Exploration of dual strategies including altered dosing and combination therapies.

Main Results:

• Structural modifications of the vitamin D backbone impact deltanoid efficacy and toxicity.
• The Vitamin D receptor (VDR) and plasma vitamin D binding protein (DBP) are key targets and factors in deltanoid activity.
• Deltanoids show potential for enhancing other chemopreventive agents.

Conclusions:

• Novel deltanoid design offers a promising approach to cancer therapy by mitigating toxicity.
• Strategies like altered dosing schedules and combination therapies (cocktail approach) are crucial for clinical success.
• Further research into SARs and pharmacokinetic profiles will optimize deltanoid development for cancer treatment.